UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~May~~December 820, 2007

GENITOPE CORPORATION

(Exact name of registrant as specified in its charter)

Delaware		000-50425		77-0436313
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)


Delaware (State or other jurisdiction of incorporation)		000-50425 (Commission File Number)		77-0436313 (I.R.S. Employer Identification No.)

6900 Dumbarton Circle
Fremont, California 94555
(Address of principal executive offices and zip code)

Registrant’s telephone number, including area code: (510) 284-3000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


o		Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


o		Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


o		Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


o		Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

TABLE OF CONTENTS

Item 2.02. Results of Operations and Financial Condition Item 9.01. Financial Statements and Exhibits Exhibt Index SIGNATURE EXHIBIT 99.1


	Item 8.01. Other Events.
	Item 9.01. Financial Statements and Exhibits.
SIGNATURE
INDEX TO EXHIBITS
EXHIBIT 99.1

Item 28.0201. ~~Results~~Other ~~of Operations and Financial Condition~~Events.

On ~~May~~December 820, 2007, Genitope Corporation issued a press release announcing the ~~financial results~~initial ~~for~~results ~~its~~of ~~first~~Genitope ~~quarter~~Corporation’s ~~ended~~Phase ~~March 31,~~3 ~~2007~~clinical trial of MyVax personalized immunotherapy. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

~~The~~As previously ~~information in this Current Report on Form 8-K~~announced, ~~including~~Genitope ~~the~~Corporation ~~exhibit~~will ~~attached~~hold ~~hereto,~~a ~~shall not~~conference becall ~~deemed~~today, ~~to be “filed” for purposes of Section~~December 1820, of2007, ~~the~~at ~~Securities~~2 ~~Exchange Act of 1934, as~~p.m. ~~amended,~~Pacific/5 orp.m. ~~otherwise~~Eastern. ~~subject~~The todial-in ~~the~~number ~~liabilities~~for ofU.S. ~~that~~and ~~Section~~Canada oris ~~Sections~~(866) 11314-4865 ~~and 12~~(apasscode 95561171)~~(2)~~. ofThe ~~the Securities~~international ~~Act~~dial-in ofis ~~1933,~~(617) 213-8050 as(passcode ~~amended~~95561171). The ~~information~~call ~~contained~~can ~~herein~~also ~~and~~be accessed in ~~the~~a ~~accompanying exhibit~~listen-only ~~shall~~mode ~~not~~on beGenitope ~~incorporated~~Corporation’s bywebsite ~~reference~~at ~~into any filing with the U~~www.Sgenitope.com. ~~Securities~~The ~~and~~webcast ~~Exchange~~will ~~Commission~~be byarchived ~~Genitope~~for ~~Corporation, whether made before or after the date hereof, regardless of any general incorporation language in such filing~~30 days.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number		Description
Exhibit 99.1		Press Release, dated May 8, 2007, entitled “Genitope Corporation Announces Financial Results for First Quarter Ended March 31, 2007.”



	99.1			Press Release entitled “Genitope Corporation Reports Initial Results of Phase 3 Clinical Trial of MyVax^® Personalized Immunotherapy,” dated December 20, 2007.

Exhibt Index

Exhibit
Number		Description
Exhibit 99.1		Press Release, dated May 8, 2007, entitled “Genitope Corporation Announces Financial Results for First Quarter Ended March 31, 2007.”

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Genitope Corporation
Dated: May 10, 2007	By:	/s/ Laura Randall Woodhead
Dated: December 20, 2007	By:	/s/ Laura Woodhead
		Laura Randall Woodhead
		Laura Woodhead
		Vice President, Legal Affairs

INDEX TO EXHIBITS


Exhibit
Number		Description

Exhibit 99.1		Press Release entitled “Genitope Corporation Reports Initial Results of Phase 3 Clinical Trial of MyVax^® Personalized Immunotherapy,” dated December 20, 2007.

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Filing Compare · GENITOPE CORP